Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat

Stock Track

02/26

Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.

For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1198741282"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1198741282\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1198741282?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198741282","market":"nz","top_or_hot":-1,"title":"Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat","media":"Stock Track","content":"<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Pharmaceuticals Soars 5.30% in Pre-Market on Strong Earnings Results and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-26 21:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.</p><p>For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1198741282","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198741282","pubTimestamp":1772111265,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"个股追踪|BioCryst Pharmaceuticals盘前大涨5.30%财报业绩强劲营收超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"Biocryst Pharmaceuticals (BCRX) saw its stock price surge 5.30% in pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The company reported quarterly adjusted earnings per share of $0.06, beating analyst estimates of $0.05 by 14.58%. Quarterly sales reached $163.284 million, exceeding consensus estimates of $151.326 million by 7.90% and representing a 24.14% increase over the same period last year.For the full year 2025, BioCryst achieved a 94% increase in revenue, driven by strong U.S. sales of its ORLADEYO product. The company posted a non-GAAP operating profit of $214.2 million, a 198% year-over-year increase, and maintained its 2026 revenue guidance. Additional positive developments include FDA approval for ORLADEYO oral pellets for pediatric patients and the completion of the Astria Therapeutics acquisition, which expanded the company's hereditary angioedema (HAE) portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}